Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
William D. WaddillDirector | Protagonist TherapeuticsPTGX | Open-market sale10b5-1 plan | 06/23 | 06/25 | 9,000 sh | $117.94 | $1,061,460 | −53.5% |
William D. WaddillDirector | Protagonist TherapeuticsPTGX | Open-market sale10b5-1 plan | 06/10 | 06/11 | 9,000 sh | $107.68 | $969,120 | −53.5% |
William D. WaddillDirector | Protagonist TherapeuticsPTGX | Open-market sale10b5-1 plan | 05/29 | 06/01 | 9,000 sh | $99.64 | $896,760 | −53.5% |
Dinesh V. Ph D. PatelPresident and CEO | Protagonist TherapeuticsPTGX | Open-market sale10b5-1 plan · Amendment | 05/12 | 05/14 | 75,000 sh | $100.12 | $7,509,000 | −12.5% |
Dinesh V. Ph D. PatelPresident and CEO | Protagonist TherapeuticsPTGX | Open-market sale | 05/12 | 05/12 | 75,000 sh | $100.12 | $7,509,000 | −12.5% |
Protagonist TherapeuticsPTGX | Open-market sale | 05/07–05/08 | 05/11 | 59,130 sh4 trades | $100.10avg. | $5,918,880 | No record | |
Asif AliCFO | Protagonist TherapeuticsPTGX | Open-market sale | 04/20 | 04/21 | 1,750 sh | $105.47 | $184,572.5 | −2.9% |
Harold E. SelickDirector | Protagonist TherapeuticsPTGX | Open-market sale | 03/26 | 03/27 | 24,000 sh | $105.00 | $2,520,000 | −28.3% |
Arturo Md MolinaChief Medical Officer | Protagonist TherapeuticsPTGX | Open-market sale | 03/26 | 03/27 | 15,000 sh | $104.79 | $1,571,850 | −15.1% |
Asif AliCFO | Protagonist TherapeuticsPTGX | Open-market sale | 03/26 | 03/27 | 24,765 sh | $104.24 | $2,581,503.6 | −29.0% |
Protagonist TherapeuticsPTGX | Open-market sale | 03/24–03/25 | 03/25 | 54,700 sh2 trades | $101.00avg. | $5,524,700 | −9.4% | |
Lewis T. WilliamsDirector | Protagonist TherapeuticsPTGX | Open-market sale | 02/17 | 02/18 | 18,000 sh | $82.42 | $1,483,560 | −69.7% |
William D. WaddillDirector | Protagonist TherapeuticsPTGX | Open-market sale | 02/06 | 02/06 | 20,000 sh | $83.68 | $1,673,600 | −71.9% |
Protagonist TherapeuticsPTGX | Open-market sale | 01/23–01/27 | 01/27 | 48,273 sh4 trades | $84.18avg. | $4,063,743.02 | −7.8% | |
Protagonist TherapeuticsPTGX | Open-market sale | 01/23–01/27 | 01/27 | 23,151 sh3 trades | $82.30avg. | $1,905,305.42 | −21.6% | |
Protagonist TherapeuticsPTGX | Open-market sale | 01/27 | 01/27 | 46,203 sh2 trades | $83.13avg. | $3,841,037.42 | −43.4% | |
Dinesh V. Ph D. PatelPresident and CEO | Protagonist TherapeuticsPTGX | Open-market sale | 01/20 | 01/21 | 34,438 sh | $82.48 | $2,840,446.24 | −5.6% |
Arturo Md MolinaChief Medical Officer | Protagonist TherapeuticsPTGX | Open-market sale | 01/20 | 01/21 | 9,514 sh | $82.48 | $784,714.72 | −8.9% |
Asif AliCFO | Protagonist TherapeuticsPTGX | Open-market sale | 01/20 | 01/21 | 8,588 sh | $82.48 | $708,338.24 | −9.9% |
Arturo Md MolinaChief Medical Officer | Protagonist TherapeuticsPTGX | Open-market sale | 25/11/17 | 25/11/19 | 2,712 sh | $84.77 | $229,896.24 | −3.2% |